ACADIA Pharmaceuticals Stock Buy or Sell? ACAD Stocks Analytic Forecasts

We present you the most up-to-date and complete review of analytical trend forecasts and views on the ACAD stock market. Experts share their opinions on what to expect from the ACADIA Pharmaceuticals Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell ACADIA Pharmaceuticals stocks.

ACADIA Pharmaceuticals Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy ACAD Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Edmund Ingham and is titled

“Acadia Pharmaceuticals: Breaking Down FY22 Earnings And Trofinetide Approval Shot”

is published on February 28 (2023) and has 3 likes. The review predicts Neutral market trend.

It summarize the following theses:

• I was bullish on Acadia back in November and its share price has climbed >30% since then.
• Revenues from Nuplazid – its only commercial drug indicated for Parkinson’s Disease Psychosis – were >$500m, but the company remains a heavy loss-maker.
• On March 13, the company will learn if the FDA has approved its drug candidate Trofinetide in Rett Syndrome.
• Management seems confident in Trofinetide based on positive Phase 3 study results showing statistically significant improvement on caregiver and physician assessment scales.
• The improvements seem somewhat marginal and an open label extension trial resulted in 46% patient discontinuation. I’m not sure that supports a Buy recommendation any longer.

The author starts his analytic review with the following:

The opinion of the author can be considered quite authoritative.
The number of 8729 followers confirms this.
Edmund Ingham is the contributor of experts community
since 2018 and has 472 works published.

One more noteworthy article is written by Stephen Ayers under the title

“Acadia’s Plateauing Nuplazid Sales And Patent Cliff Overshadow Positive Trofinetide Development”

on February 15 (2023) and has 3 likes. The expert reflects Bearish trend of the market.

Нis theses make you think about whether to add ACAD stocks to your investment portfolio or not, and helps to work out your own ACADIA Pharmaceuticals stock selling strategies:

• Rett Syndrome is a rare genetic disorder affecting females that results in a slow deterioration in gross motor function, with respiratory illnesses and seizure-related conditions as the most common causes.
• Trofinetide is a synthetic glycine-proline-glutamate analog increasing brain-derived neurotrophic factor expression, essential for neuronal and synaptic development.
• A phase 3 study showed significant improvement in primary and secondary endpoints in 187 Rett Syndrome patients, but mild-to-moderate diarrhea and vomiting led to higher treatment discontinuation rates.
• Trofinetide could generate $500 million annually for Acadia. The drug’s PDUFA date is March 12, 2023. Barring unpredictable surprises, like CMC issues, approval is anticipated.
• However, Acadia’s leading drug Nuplazid failed to expand its indications and with trofinetide’s launch, Acadia’s valuation may not increase substantially. Acadia may owe Neuren millions of dollars and have to raise additional capital soon. My personal recommendation is to “Sell”.

Stephen Ayers starts analysis with such words:

The opinion of the author can be considered quite authoritative.
The number of 3926 followers confirms this.
Stephen Ayers is the contributor of experts community since 2017. Has already published at least 172 articles.

Another analysis presented by Bret Jensen came out on January 16 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for ACAD stocks. It sounds like

“Acadia Pharmaceuticals: What’s Ahead In 2023”

Article has got 7 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the ACADIA Pharmaceuticals Inc., the expert says the following:

• Today, we are circling back on mid-cap biopharma ACADIA Pharmaceuticals Inc. for the first time since the spring of 2021.
• The company had one major disappointment in 2022, but has some potential new drug approvals on the horizon.
• An investment analysis follows in the paragraphs below.

And here, what comes first:

This author is very popular among the auditory. He has 45828 followers.

Bret Jensen is the contributor of experts community since 2010 and has at least 3948 analytic reviews published.